180 Life Sciences Corp. (ATNF) - Q2 2025 10-Q Summary
Business Context and Reporting Period
This filing covers the quarterly period ended June 30, 2025. 180 Life Sciences Corp. is a clinical-stage biotechnology company that has pivoted its strategic focus. While it retains legacy biotechnology assets (fibrosis/anti-TNF and CBD derivatives), it has returned its alpha-7 nicotinic acetylcholine receptor assets to Stanford University. In September 2024, the Company acquired a blockchain-based "Gaming Technology Platform" from Elray Resources, Inc., intending to launch an online iGaming casino. The Company is currently evaluating strategic options for its biotechnology assets, including potential sale or disposition.
Key Financial Metrics
| Metric | Six Months Ended June 30, 2025 | Six Months Ended June 30, 2024 |
|---|---|---|
| Revenue | $0 | $0 |
| Net Loss | $(4,095,836) | $(1,057,963) |
| Operating Expenses | $4,103,383 | $3,939,206 |
| Cash Used in Operating Activities | $(1,984,787) | $(306,247) |
| Cash Balance (End of Period) | $2,218,331 | $1,146,288 |
| Working Capital | $(2,241,478) Deficit | $1,636,486 Surplus |
| Total Debt (Current) | $1,412,445 | $147,889 |
| Accumulated Deficit | $(145,619,180) | $(128,401,620) |
Material Changes vs. Prior Period
- Increased Net Loss: Net loss increased by 287% year-over-year, driven primarily by higher settlement expenses and stock-based compensation, offset by a lack of the significant insurance proceeds received in the prior year.
- Settlement Expenses: The Company incurred approximately $751,000 in settlement expenses during the six months ended June 30, 2025, related to agreements with AmTrust International, Dr. Marlene Krauss, and Elray Resources. This contrasts with a gain on settlement of liabilities in the prior year.
- Stock-Based Compensation: Increased by approximately $427,000 compared to the prior year due to new awards granted to directors and officers.
- Debt Increase: Current loans payable increased significantly to $1.41 million from $148,000 in the prior year, largely due to a new loan for insurance financing ($613,700) and related party loans.
- Equity Transactions: The Company issued 752,873 shares of common stock to settle liabilities. Additionally, 1,000,000 shares of Series B Convertible Preferred Stock were converted into 1,318,000 shares of common stock in March 2025.
Outlook, Risks, and Management Commentary
- Going Concern: The Company has raised substantial doubt about its ability to continue as a going concern. With a monthly cash burn of approximately $274,000 and no revenue, management estimates current cash will last only until December 2025. Significant additional capital is required to commercialize the iGaming platform and maintain operations.
- iGaming Commercialization: Management estimates the cost to fully commercialize the Gaming Technology Platform (including licensing, front-end development, and marketing) ranges from $3 million to over $5 million. No formal bids have been received for the sale of biotechnology assets to date.
- Legal and Regulatory Risks:
- University of Oxford: The Company owes approximately $2 million to the University of Oxford for license fees. Oxford has engaged legal counsel and threatened legal proceedings, including a potential wind-up petition against a UK subsidiary.
- Nasdaq Compliance: The Company regained compliance with Nasdaq's stockholders' equity rule in October 2024 but is subject to a one-year mandatory panel monitor. Failure to maintain compliance could result in delisting.
- Internal Controls: Management concluded that disclosure controls and procedures were not effective as of June 30, 2025, citing a material weakness related to limited accounting resources.
- Capital Raising: The Company is in preliminary discussions regarding capital raises, which may result in significant dilution. A reverse stock split and increase in authorized shares are pending shareholder approval.
Investor Verification Checklist
- Cash Runway: Verify the accuracy of the $274,000 monthly burn rate and the December 2025 liquidity horizon.
- Oxford Debt: Confirm the status of negotiations regarding the $2 million owed to the University of Oxford and the risk of asset seizure or subsidiary wind-up.
- iGaming Costs: Assess the feasibility of raising the estimated $3M-$5M required to launch the casino platform given current market conditions.
- Settlement Obligations: Review the terms of the Elray Settlement Agreement, specifically the $650,000 payable to Luxor Capital from future capital raise proceeds.
- Nasdaq Status: Monitor the Company's compliance with the one-year mandatory panel monitor period to avoid delisting.